Clinical trial
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In…
NCT00473460 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00473460 |
|---|---|
| Title | Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis |
| Official title | A Double-blind, Randomized, Placebo-controlled Study to Investigate Chronic Intermittent-pulse-therapy of Moxifloxacin as a Prevention of Acute in Exacerbation Out-patients With Chronic Bronchitis. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Diseases, Bronchitis, Chronic |
| Intervention type | Drug |
| Interventions | Avelox (Moxifloxacin, BAY12-8039), Placebo |
| Enrollment | 1,404 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | May 15, 2007 |
| Last update posted | Oct 28, 2014 |
| Countries | Andorra, Argentina, Brazil, Chile, France, Germany, Greece, Ireland, Israel, Italy, Mexico, South Africa and 3 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: